Niosomes: A review of their structure, properties, methods of preparation, and medical applications

Asian Biomedicine

Volumn 11, Issue 4, 2017, Pages 301-313

  Yeo, Pei Ling ^a   Lim, Chooi Ling ^a   Chye, Soi Moi ^a   Ling, Anna Pick Kiong ^a   Koh, Rhun Yian ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Drug delivery system; Medical applications; Methods of preparation; Niosomes; Structure

Indexed keywords

ALPHA TOCOTRIENOL; AMAROGENTIN; AMPHOPHILE; ARTEMISININ; BECLOMETASONE DIPROPIONATE; BLEOMYCIN; CHOLESTEROL; CISPLATIN; CURCUMIN; DIALLYL DISULFIDE; DOXORUBICIN; FLUCONAZOLE; FLUOROURACIL; FLURBIPROFEN; GALLIDERMIN; GENTAMICIN; ISONIAZID; ITRACONAZOLE; LIPOSOME; METHOTREXATE; MITOXANTRONE; NIOSOME; NISIN; NONIONIC SURFACTANT; RESVERATROL; SERRATIOPEPTIDASE; TAMOXIFEN CITRATE; UNINDEXED DRUG; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL INFECTION; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; HUMAN; INFLAMMATION; LEISHMANIASIS; LIPOSOMAL DELIVERY; LUNG DISEASE; MYCOSIS; NEOPLASM; NONHUMAN; REVIEW; STRUCTURE ANALYSIS; SYNTHESIS;

EID: 85048551741     PISSN: 19057415     EISSN: 1875855X     Source Type: Journal    
DOI: 10.1515/abm-2018-0002     Document Type: Review

References (124)

1. Allen TM. Liposomal drug formulations: rationale for development and what we can expect for the future. Drugs. 1998; 56:747-56.
2. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8:473-80.
3. Chen X, Huang W, Wong BC, Yin L, Wong YF, Xu M, et al. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine. 2012; 7:1139-48.
4. Shek PN, Suntres ZE, Brooks JI. Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target. 1994; 2:431-42.
5. Parthasarathi G, Udupa N, Umadevi P, Pillai G. Niosome encapsulated of vincristine sulfate: improved anticancer activity with reduced toxicity in mice. J Drug Target. 1994; 2:173-82.
6. Moazeni E, Gilani K, Sotoudegan F, Pardakhty A, Najafabadi AR, Ghalandari R, et al. Formulation and _in_ vitro_ evaluation of ciprofloxacin containing niosome for pulmonary delivery. J Microencapsul. 2010; 27:618-27.
7. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharm Sin B. 2011; 1:208-19.
8. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998; 172:33-70.
9. Rangasamy M, Ayyasamy B, Raju S, Gummadevelly S, Shaik S. Formulation and in vitro evaluation of niosome encapsulated acyclovir. J Pharm Res. 2008; 1:163-6.
10. Bhaskaran S, Lakshmi PK. Comparative evaluation of niosome formulations prepared by different techniques. Acta Pharma Sci. 2009; 51:27-32.
11. Negi LM, Garg AK, Chauhan M. Ultradeformable vesicles: concept and execution. Pharma Times. 2009; 41:11-4.
12. Sankar V, Ruckmani K, Jailani S, Ganesan KS, Sharavanan SP. Niosome drug delivery system: advances and medical applications - an overview. Pharmacologyonline. 2009; 2:926-32.
13. Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci. 1995; 58:1-55.
14. Bouwstra JA, van Hal DA, Hofland HEJ, Junginger HE. Preparation and characterization of nonionic surfactant vesicles. Colloids Surf A: Physicochem Eng Aspects. 1997; 123-124:71-80.
15. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes-non-ionic surfactant vesicles. J Pharm Pharmacol. 1985; 37:863-68.
16. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: an updated review. Int J Pharma Investig. 2012; 2:2-11.
17. Thacharodi D, Rao KP. Development and _in_ vitro_ evaluation of chitosan-based transdermal drug delivery system for the controlled delivery of propranolol hydrochloride. Biomaterials. 1995; 16:145-8.
18. Krishna R, Pandit JK. Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. J Pharm Pharmacol. 1996; 48:367-70.
19. Bhat M, Shenoy DS, Udupa N, Srinivas CR. Optimization of delivery of betamethasone-dipropionate from skin preparation. Indian Drugs. 1995; 32:211-4.
20. Diljyot K. Niosomes: a new approach to targeted drug delivery. Int J Pharm Phytopharm Res. 2012; 2:53-9.
21. Malhotra M, Jain NK. Niosomes as drug carriers. Indian Drugs. 1994; 31:81-6.
22. Giddi HS, Arunagirinathan MA, Bellare JR. Self-assembled surfactant nano-structures important in drug delivery: a review. Indian J Exp Biol. 2007; 45:133-59.
23. Biju SS, Talegaonkar S, Mishra PR, Khar RK. Vesicular systems: an overview. Indian J Pharm Sci. 2006; 68:141-53.
24. Bandyopadhyay P, Johnson M. Fatty alcohols or fatty acids as niosomal hybrid carrier: effect on vesicle size, encapsulation efficiency and in vitro dye release. Colloids Surf B Biointerfaces. 2007; 58:68-71.
25. Shan W, Liu H, Shi J, Yang L, Hu N. Self-assembly of electroactive layer-by-layer films of heme proteins with anionic surfactant dihexadecyl phosphate. Biophys Chem. 2008; 134:101-9.
26. Gandhi A, Sen SO, Paul A. Current trend in niosome as vesicular drug delivery system. Asian J Pharm Life Sci. 2012; 2:339-53.
27. Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee SA, Behera M, et al. Niosome: a future of targeted drug delivery systems. J Adv Pharm Tech Res. 2010; 1:374-80.
28. Sahin NO. Niosomes as nanocarrier systems. In: Mozafari MR, editor. Nanomaterials and nanosystems for biomedical applications. Dordrecht: Springer; 2007. p. 67-82.
29. Keservani RK, Sharma AK, Ayaz Md, Kesharwani RK. Novel drug delivery system for the vesicular delivery of drug by the niosomes. Int J Res Controlled Release. 2011; 1:1-8.
30. Khandare JN, Madhavi G, Tamhankar BM. Niosomes novel drug delivery system. The Eastern Pharmacist. 1994; 37:61-4.
31. Jayaraman SC, Ramachandran C, Weiner N. Topical delivery of erythromycin from various formulations: an _in_ vivo_ hairless mouse study. J Pharm Sci. 1996; 85:1082-84.
32. Raja NRA, Pillai GK, Udupa N, Chandrashekhar G. Anti-inflammatory activity of niosome encapsulated diclofenac sodium in arthritic rats. Indian J Pharmacol. 1994; 26:46-8.
33. Chauhan S, Luorence MJ. The preparation of polyoxyethylene containing non-ionic surfactant vesicles. Cox B, editor. British Pharmaceutical Conference 1989, Science Proceedings 126th Meeting; 1989 September 11-14; Keele, United Kingdom. London: Royal Pharmacological Society of Great Britain. J Pharm Pharmacol. 1989; 41 Suppl:6P.
34. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta. 1985; 816:294-302.
35. Verma AK, Bindal JC. A vital role of niosomes on controlled and novel drug delivery. Indian J Novel Drug Deliver. 2011; 3:238-46.
36. Aggarwal D, Garg A, Kaur IP. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J Pharm Pharmacol. 2004; 56:1509-17.
37. Hao Y, Zhao F, Li N, Yang Y, Li K. Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm. 2002; 244:73-80.
38. Sankhyan A, Pawar P. Recent trends in niosome as vesicular drug delivery system. J Appl Pham Sci. 2012; 2:20-32.
39. Udupa N. Niosomes as drug carriers. In: Jain NK, editor, Controlled and novel drug delivery. New Delhi: CBS Publishers and Distributors; 2002. p. 292-303.
40. Muzzalupo R, Tavano L, Lai F, Picci N. Niosomes containing hydroxyl additives as percutaneous penetration enhancers: effect on the transdermal delivery of sulfadiazine sodium salt. Colloids Surf B Biointerfaces. 2014; 123:207-12.
41. Rogerson A, Cummings J, Florence AT. Adriamycin-loaded niosomes: drug entrapment, stability and release. J Microencapsul. 1987; 4:321-8.
42. Arunothayanun P, Bernard M-S, Craig DQM, Uchegbu IF, Florence AT. The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from hexadecyl diglycerol ether. Int J Pharm. 2000; 201:7-14.
43. Biswal S, Murthy PN, Sahu J, Sahoo P, Amir F. Vesicles of non-ionic surfactants (niosomes) and drug delivery potential. Int J Pharm Sci Nanotech. 2008; 1:1-8.
44. Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm. 1999; 185:23-5.
45. Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design. AAPS PhamSciTech. 2007; 8:43. doi: 10.1208/pt0804086.
46. Ibrahim MMA, Sammour OA, Hammad MA, Megrab NA. In vitro evaluation of proniosomes as a drug carrier for flurbiprofen. AAPS PhamSciTech. 2008; 9:782-90.
47. Reddy BS, Padman JSC, Santosh V. Niosomes as nanocarrier systems: a review. Int J Pharm Sci Res. 2012; 3:1560-68.
48. Zasadzinski JA, Wong B, Forbes N, Gary B, Wu G. Novel methods of enhanced retention in and rapid, targeted release from liposomes. Curr Opin Colloid Interface Sci. 2011; 16:203-14.
49. Yoo J-W, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev. 2011; 63:1247-56.
50. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid - An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009; 73:1-15.
51. Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a_ controlled and novel drug delivery system. Biol Pharm Bull. 2011; 34:945-53.
52. Mujoriya RZ, Dhamande K, Bodla RB. Niosomal drug delivery system - a review. Int J Appl Pharm. 2011; 3:7-10.
53. Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother. 1999; 44:791-4.
54. Kieburtz KD, Seidlin M, Lambert JS, Dolin R, Reichman R, Valentine F. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxy-inosine. J Acquir Immune Defic Syndr. 1992; 5:60-4.
55. Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao RB, Rambhau D. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci. 2002; 251:360-65.
56. Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAPS PhamSciTech. 2010; 11:1119-27.
57. Cummings J, Stuart JFB, Calman KC. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1984; 311:125-33.
58. Udupa N, Chandraprakash KS, Umadevi P, Pillai GK. Formulation and evaluation of methotrexate niosomes. Drug Dev Indust Pharm. 1993; 19:1331-42.
59. Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm. 2008; 353:233-42.
60. Nesaretnam K, Guthrie N, Chambers AF, Carroll KK. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids. 1995; 30:1139-43.
61. Fu J-Y, Tan DMY, Er HM, Chen YS, Nesaretnam K. Tumor-targeted niosome as novel carrier for intravenous administration of tocotrienol. Sriamornsak P, Limmatvapirat S, Piriyaprasarth S, editors. Asian Federation for Pharmaceutical Sciences (AFPS) 2015 Conference; 2015 Nov 25-27. Bangkok, Thailand. Asian J Pharm Sci. 2016; 11:79-80.
62. Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 2015; 35:645-51.
63. Xu YQ, Chen WR, Tsosie JK, Xie X, Li P, Wan J, et al. Niosome encapsulation of curcumin: characterization and cytotoxic effect on ovarian cancer cells. J Nanomater. 2016; 2016:6365295. 9p. doi: 10.1155/2016/6365295.
64. Sharma V, Anandhakumar S, Sasidharan M. Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery. Mater Sci Eng C Mater Biol Appl. 2015; 56:393-400.
65. Antimalaria Coordinating Research Group. Antimalaria studies on qinghaosu. Chin Med J. 1979; 92:811-6.
66. Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012; 2012:247597. doi: 10.1155/2012/247597.
67. Li Q, Weina PJ, Milhous WK. Pharmacokinetic and pharmaco-dynamic profiles of rapid-acting artemisinins in the antimalarial therapy. Curr Drug Ther. 2007; 2:210-23.
68. Dwivedi A, Mazumder A, du Plessis L, du Preez JL, Haynes RK, du Plessis J. In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. Nanomedicine. 2015; 11:2041-50.
69. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971; 25:270-75.
70. Shaker DS, Shaker MA, Hanafy MS. Cellular uptake, cytotoxicity and_in-vivo_ evaluation of Tamoxifen citrate loaded niosomes. Int J Pharm. 2015; 493:285-94.
71. Tila D, Yazdani-Arazi SN, Ghanbarzadeh S, Arami S, Pourmoazzen Z. pH-sensitive, polymer modified, plasma stable niosomes: promising carriers for anti-cancer drugs. EXCLI J. 2015; 14:21-32.
72. Li M, Tang Z, Zhang Y, Lv S, Li Q, Chen X. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis. Acta Biomater. 2015; 18:132-43.
73. Kanaani L, Javadi I, Ebrahimifar M, Ebrahimi shahmabadi H, Akbarzadeh Khiyavi A, Mehrdiba T. Effects of cisplatin-loaded niosomal nanoparticles on BT-20 human breast carcinoma cells. Asian Pac J Cancer Prev. 2017; 18:365-8.
74. Shilpa S, Srinivasan BP, Chauhan M. Niosomes as vesicular carriers for delivery of proteins and biologicals. Int J Drug Delivery. 2011; 3:14-24.
75. Terzano C, Allegra L, Alhaique F, Marianecci C, Carafa M. Non-phospholipid vesicles for pulmonary glucocorticoid delivery. Eur J Pharm Biopharm. 2005; 59:57-62.
76. Singh G, Dwivedi H, Saraf SK, Saraf SA. Niosomal delivery of isoniazid - development and characterization. Trop J Pharm Res. 2011; 10:203-10.
77. Jain CP, Vyas SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics. Indian J Pharm Sci. 2006; 68:575-8.
78. Kaur K, Gupta A, Narang RK, Murthy RSR. Novel drug delivery system: desired feat for tuberculosis. J Adv Pharm Tech Res. 2010; 1:145-63.
79. Mullaicharam AR, Murthy RSR. Lung accumulation of niosomeentrapped gentamicin sulfate follows intravenous and intratracheal administration in rats. J Drug Deliv Sci Tech. 2006; 16:109-13.
80. Muzzalupo R. Niosomes and proniosomes for enhanced skin delivery. In: Dragicevic N, Maibach H, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement. Heidelberg: Springer; 2016. p. 147-60.
81. Fathalla D, Abdel-Mageed A, Abdel-Hamid F, Ahmed M. In-vitro and in-vivo evaluation of niosomal gel containing aceclofenac for sustained drug delivery. Int J Pharm Sci Res. 2014; 1:105. doi: 10.15344/2394-1502/2014/105.
82. Kumbhar D, Wavikar P, Vavia P. Niosomal gel of lornoxicam for topical delivery: _in_ vitro_ assessment and pharmacodynamic activity. AAPS PhamSciTech. 2013; 14:1072-82.
83. Kamboj S, Saini V, Bala S, Sharma G. Formulation and characterization of drug loaded niosomal gel for anti-inflammatory activity. Int J Med Health Biomed Bioeng Pharm Eng. 2013; 7:877-81.
84. Shinde UA, Kanojiya SS. Serratiopeptidase niosomal gel with potential in topical delivery. J Pharm (Cario). 2014; 2014:9. doi: 10.1155/2014/382959.
85. Fukai T, Satoh K, Nomura T, Sakagami H. Preliminary evaluation of antinephritis and radical scavenging activities of glabridin from Glycyrrhiza glabra. Fitoterapia. 2003; 74:624-9.
86. Morteza-Semnani K, Saeedi M, Shahnavaz B. Comparison of antioxidant activity of extract from roots of licorice (Glycyrrhiza glabra L.) to commercial antioxidants in 2% hydroquinone cream. J Cosmet Sci. 2003; 54:551-8.
87. Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release. 2005; 106:99-110.
88. Matsui S, Matsumoto H, Sonoda Y, Ando K, Aizu-Yokota E, Sato T, et al. Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. Int Immunopharmacol. 2004; 4:1633-44.
89. Marianecci C, Rinaldi F, Mastriota M, Pieretti S, Trapasso E, Paolino D, et al. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release. 2012; 164:17-25.
90. Priprem A, Janpim K, Nualkaew S, Mahakunakorn P. Topical niosome gel of Zingiber cassumunar Roxb. extract for anti-inflammatory activity enhanced skin permeation and stability of compound D. AAPS PhamSciTech. 2016; 17:631-9.
91. Leelarungrayub J, Manorsoi J, Manorsoi A. Anti-inflammatory activity of niosomes entrapped with Plai oil (Zingiber cassumunar Roxb.) by therapeutic ultrasound in a rat model. Int J Nanomedicine. 2017; 12:2469-76.
92. Jang M, Cai L, Udeani GO. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275:218-20.
93. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomás-Barberán FA, García-Conesa MT, Espín JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Cur Pharma Des. 2013; 19:6064-93.
94. Davidov-Pardo G, McClements DJ. Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues. Trends Food Sci Technol. 2014; 38:88-103.
95. Negi P, Aggarwal M, Sharma G, Rathore C, Sharma G, Singh B, et al. Niosome-based hydrogel of resveratrol for topical applications: an effective therapy for pain related disorder(s). Biomed Pharmacother. 2017; 88:480-87.
96. van Sorge AA, Wijnen PH, van Delft JL, Coré-Bodelier VM, van Haeringen NJ. Flurbiprofen, S(+), eyedrops: formulation, enantiomeric assay, shelf life and pharmacology. Pharm World Sci. 1999; 21:91-5.
97. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Delivery Rev. 1995; 16:39-43.
98. Zhang W, Prausnitz MR, Edwards A. Model of transient drug diffusion across cornea. J Control Release. 2004; 99:241-58.
99. El-Sayed MM, Hussein AK, Sarhan HA, Mansour HF. Flurbiprofen-loaded niosomes-in-gel system improves the ocular bioavailability of flurbiprofen in the aqueous humor. Drug Dev Ind Pharm. 2017; 43:902-10.
100. Wagh VD, Deshmukh OJ. Itraconazole niosomes drug delivery system and its antimycotic activity against Candida albicans. ISRN Pharm. 2012; 2012:653465.
101. Alam M, Zubair S, Farazuddin M, Ahmad E, Khan A, Zia Q, et al. Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis. Nanomedicine. 2013; 9:247-56.
102. Fetih G. Fluconazole-loaded niosomal gels as a topical ocular drug delivery system for corneal fungal infections. J Drug Deliv Sci Technol. 2016; 35:8-15.
103. Gupta A, Kar HK. Antidermatophytic activity of miconazole nanoformulation against Trichophyton rubrum. Asian Pac J Trop Dis. 2015; 5:707-10.
104. de Arauz LJ, Jozala AF, Mazzola PG, Penna TCV. Nisin biotech-nological production and application: a review. Trends Food Sci Technol. 2009; 20:146-54.
105. Boziaris IS, Adams MR. Effect of chelators and nisin produced in situ on inhibition and inactivation of Gram negatives. Int J Food Microbiol. 1999; 53:105-13.
106. Kopermsub P, Mayen V, Warin C. Potential use of niosomes for encapsulation of nisin and EDTA and their antibacterial activity enhancement. Food Res Int. 2011; 44:605-12.
107. Kellner R, Jung G, Hörner T, Zähner H, Schnell N, Entian KD, et al. Gallidermin: a new lanthionine-containing polypeptide antibiotic. Eur J Biochem. 1988; 177:53-9.
108. Manosroi A, Khanrin P, Lohcharoenkal W, Werner RG, Götz F, Manosroi W, et al. Transdermal absorption enhancement through rat skin of gallidermin loaded in niosomes. Int J Pharm. 2010; 392:304-10.
109. Burdock G. Review of the biological properties and toxicity of bee propolis (propolis). Food Chem Toxicol. 1998; 36:347-63.
110. Patel J, Ketkar S, Patil S, Fearnley J, Mahadik KR, Paradkar AR. Potentiating antimicrobial efficacy of propolis through niosomal-based system for administration. Integr Med Res. 2015; 4:94-101.
111. Zubairu Y, Negi LM, Iqbal Z, Talegaonkar S. Design and development of novel bioadhesive niosomal formulation for the transcorneal delivery of anti-infective agent: _In-vitro_ and_ex-vivo investigations. Asian J Pharm Sci. 2015; 10:322-30.
112. Sohrabi S, Haeri A, Mahboubi A, Mortazavi A, Dadashzadeh S. Chitosan gel-embedded moxifloxacin niosomes: an efficient antimi-crobial hybrid system for burn infection. Int J Biol Macromol. 2016; 85:625-33.
113. Wagner VE, Iglewski BH. Pseudomonas_ aeruginosa_ biofilms in CF infection. Clin Rev Allergy Immunol. 2008; 35:124-34.
114. Mahdiun F, Mansouri S, Khazaeli P, Mirzaei R. The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas_ aeruginosa. Microb Pathog. 2017; 107:129-35.
115. Borowska K, Wolowiec S, Rubaj A, Glowniak K, Sieniawska E, Radej S. Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene-In vivo study. Int J Pharm. 2012; 426:280-83.
116. Kassem AA, Abd El-Alim SH, Asfour MH. Enhancement of 8-methoxypsoralen topical delivery via nanosized niosomal vesicles: formulation development, in vitro and in vivo evaluation of skin deposition. Int J Pharm. 2017; 517:256-68.
117. Jacob S, Nair AB, Al-Dhubiab BE. Preparation and evaluation of niosome gel containing acyclovir for enhanced dermal deposition. J Liposome Res. 2017; 27:283-92.
118. Cortesi R, Esposito E. Acyclovir delivery systems. Expert Opin Drug Deliv. 2008; 5:1217-30.
119. Mashal M, Attia N, Puras G, Martínez-Navarrete G, Fernández E, Pedraz JL. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. J Control Release. 2017; 254:55-64.
120. Opanasopit P, Leksantikul L, Niyomtham N, Rojanarata T, Ngawhirunpat T, Yingyongnarongkul BE. Cationic niosomes an effective gene carrier composed of novel spermine-derivative cationic lipids: effect of central core structures. Pharm Dev Technol. 2017; 22:350-59.
121. Hashemi Dehaghi M, Haeri A, Keshvari H, Abbasian Z, Dadashzadeh S. Dorzolamide loaded niosomal vesicles: comparison of passive and remote loading methods. Iran J Pharm Res. 2017; 16:413-22.
122. Hsu CY, Chen CH, Aljuffali IA, Dai YS, Fang JY. Nanovesicle delivery to the liver via retinol binding protein and platelet-derived growth factor receptors: how targeting ligands affect biodistribution. Nanomedicine (Lond). 2017; 12:317-31.
123. Moghassemi S, Hadjizadeh A, Hakamivala A, Omidfar K. Growth factor-loaded nano-niosomal gel formulation and characterization. AAPS PharmSciTech. 2017; 18:34-41.
124. Moghassemi S, Hadjizadeh A, Omidfar K. Formulation and characterization of bovine serum albumin-loaded niosome. AAPS PharmSciTech. 2017; 18:27-33.